Pluri

Name

Pluri

Legal name

Pluri Inc.

Website

https://pluri-biotech.com

Company type

Public

Founded year

2003

Operating status

Operating

Headcount range

101–250 employees

Ownership category

akta.pro rank

Product category

Biotechnology — Cell Therapy & CDMO Services

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish) (HLAAABAG)

akta.pro secondary industries

Cell Therapy CDMO (HLAGABAD), Cell Therapy Developers (Allogeneic/Off-the-shelf) (HLAAABAB), Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE)

Keywords

• Cell therapy development
• 3D cell expansion
• Biopharmaceutical CDMO services
• Cultivated meat production
• Regenerative medicine solutions

Headquarters

HQ city

Haifa

HQ country

Israel

HQ region

Middle East

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Supply Chain, Marketing or Sales

Revenue model

1. CDMO Services: Contract Development and Manufacturing Organization services for cell therapy products, supporting partners from preclinical development through clinical and commercial production. Revenue generated through service fees for manufacturing, process development, and related services.
2. Product Commercialization (Subsidiaries): Revenue from commercialized products through wholly-owned subsidiaries including Cellav (exosome-based skincare), Kokomodo (cultivated cacao), and Coffeesai (cell-based coffee).
3. Cell Therapy Development: Development and potential commercialization of proprietary cell therapy product candidates including PLX-R18 for hematology and ARS, PLX-PAD for critical limb ischemia and osteoarthritis, and MAIT cell platform for cancer immunotherapy.
4. Technology Licensing and Partnerships: Revenue from licensing the proprietary 3D cell expansion technology to partners in various industries including foodtech, agtech, and biotechnology through joint ventures and strategic collaborations.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels7 records

Core offering

Pluri develops and commercializes a patented three-dimensional (3D) cell expansion technology platform used to manufacture placenta-derived allogeneic cell therapy product candidates (PLX-R18 and PLX-PAD), a placental MAIT cell immunotherapy platform, and proprietary contract development and manufacturing (CDMO) services for cell-based therapies. The same platform supports subsidiary and joint-venture products in cultivated meat (Ever After Foods), cultivated cacao (Kokomodo), cell-based coffee (Coffeesai), and exosome-based regenerative skincare (Cellav), alongside cryogenic supply chain services (FreezOnTime).

Product overview

Pluri operates as a biotechnology company with a patented 3D cell expansion technology platform that enables manufacturing of cell-based products across multiple industries. The company functions through distinct business verticals: PluriHealth (regenerative medicine with PLX-R18 and PLX-PAD cell therapy products), PluriFood (cultivated meat through Ever After Foods joint venture), PluriAgtech (cell-based coffee via Coffeesai and cacao via Kokomodo subsidiary), and PluriCDMO (contract manufacturing services). The portfolio includes wholly-owned subsidiaries such as Cellav (exosome-based skincare with Regenativo+ and Placento+ products) and the FreezOnTime cryogenic logistics service. The platform supports both allogeneic off-the-shelf cell therapies and cultivated food/agtech products.

Differentiator

Problem solved

Functional benefit

Brands

• Cellav: Wholly-owned subsidiary focused on exosome-based regenerative skincare products using cell expansion technology
• Kokomodo
• Ever After Foods
• Coffeesai
• FreezOnTime
• Plurinuva

Products and services

• PluriCDMO Contract Development and Manufacturing Organization (CDMO) service offering full-service manufacturing support for cell-based therapies, from preclinical development through clinical and commercial production. Provides cell isolation, process development, scale-up, GMP manufacturing, cryopreservation, storage, and global logistics for pharmaceutical and biotech customers.
• PLX-R18 Placenta-derived allogeneic cell therapy product candidate for the treatment of Acute Radiation Syndrome (ARS) and hematological disorders, including poor graft function after hematopoietic cell transplantation. PLX-R18 stimulates bone marrow to generate all three blood cell lines and has received FDA Orphan Drug Designation and IND clearance.
• PLX-PAD Placenta-derived stromal cell therapy product candidate for the treatment of critical limb ischemia and knee osteoarthritis, with demonstrated increases in muscle strength in clinical studies and hypothesized to induce systemic anti-inflammatory effects.
• Ever After Foods (Cultivated Meat Joint Venture) Joint venture with Tnuva Group, Israel's largest food producer, to produce cultivated meat products at scale using Pluri's 3D cell expansion technology for affordable and sustainable animal protein alternatives.
• Kokomodo Cultivated Cacao Cultivated cacao produced in controlled bioreactor environments using proprietary cellular agriculture technology to deliver consistent, high-quality cacao without land-intensive farming, targeting gourmet chocolate and functional wellness markets.
• Coffeesai Cell-Based Coffee Cell-based coffee produced via Pluri's 3D cell expansion platform, targeting roughly 98% reduction in water usage and 95% reduction in farmland usage versus traditional coffee cultivation, developed through subsidiary Coffeesai.
• MAIT Cell Immunotherapy Platform Placental allogeneic MAIT (Mucosal Associated Invariant T) cell platform for immunotherapy treatment of solid tumors. MAIT cells offer lower alloreactivity profiles, minimizing Graft-versus-Host Disease risk and serving as a first-in-class off-the-shelf therapy expanded via Pluri's 3D cell technology.
• Cellav Regenerative Skincare (Regenativo+ and Placento+) Regenerative aesthetic products (Regenativo+ and Placento+) using exosome-based regenerative skincare through Cellav, Pluri's wholly-owned subsidiary; supplied in lyophilized powder and booster vial duo for professional topical use after aesthetic procedures, with clinically validated ingredients and statistically significant improvements in studies.
• FreezOnTime Cryogenic Supply Chain Services Cryogenic supply chain service offering GMP/GDP-compliant solutions for handling, storage, and global transportation of cryopreserved materials, including LN2 dry shipper rental, calibration, site initiation, and temperature-controlled storage for clinical trial logistics.

Quantifiable outcome

• Cells from a single placenta can treat more than 20,000 patients
• +4 more outcomes

Named customers5 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature8 records

Partnerships

13 partnerships are on record, tiered major, core and minor.

• Resbiomed Technologies OODmajorStrategic or Co-development Partner · 22 January 2026Collaboration program to develop placenta-derived collagen-rich biomaterials for regenerative medicine applications. Completed initial process development and feasibility, advancing to next phase focusing on manufacturing readiness.
• Remedy Cell Ltd.coreStrategic or Co-development Partner · 22 December 2025Expanded manufacturing agreement for production of clinical-grade batches for Phase 1b clinical trials. Successfully completed GMP implementation, engineering runs, and clinical-grade manufacturing for secretome-based treatments for fibrotic diseases.
• Miss Universe SkincarecoreGTM or Marketing Partner · 11 November 2025Collaboration to develop exosome-enhanced regenerative skincare products. First product expected to launch H1 2026 with global distribution through Miss Universe Skincare network.
• Instituto del Café de Chiapas (INCAFECH)majorStrategic or Co-development Partner · 8 October 2025Strategic collaboration through subsidiary Coffeesai to advance cell-based coffee manufacturing in Mexico.
• Kokomodo Ltd.coreStrategic or Co-development Partner · 28 April 2025Pluri acquired approximately 71% of Kokomodo for $4.5 million payable in shares. Kokomodo specializes in cultivated cacao using Pluri's cell production technology to address environmental challenges and sustainable cacao demand.
• HemafundmajorStrategic or Co-development Partner · 5 March 2025Exclusive collaboration agreement to enhance Ukraine's radiation emergency preparedness using Pluri's cell therapy technologies.
• Bar-Ilan UniversitymajorStrategic or Co-development Partner · 28 October 2024Collaboration to advance cancer immunotherapy for solid tumors, supported by Israel Innovation Authority funding.
• EU ConsortiumminorStrategic or Co-development Partner · 8 July 2024€1 million proof of concept agreement to enhance global sustainable vegetable supply using plant cell culture technology.
• Ever After FoodscoreStrategic or Co-development Partner · 18 June 2024Subsidiary secured $10 million strategic investment to solve cultivated food scalability challenges and expand production capabilities.
• WilkminorStrategic or Co-development Partner · 20 May 2024Collaboration to develop human breast milk-derived food production on commercial scale for elderly nutrition applications.
• Tnuva GroupcoreStrategic or Co-development Partner · 1 February 2022Landmark food-tech joint venture to establish cultured food platform (Plurinuva). Tnuva, Israel's largest food producer, leverages Pluri's cell expansion technology to produce cultivated meat at scale for affordable prices.
• KadimastemmajorStrategic or Co-development PartnerCDMO selected to manufacture Kadimastem's novel cell therapy product candidates for clinical development.
• CargillmajorStrategic or Co-development PartnerEU-funded collaboration to evaluate functionality, sensory performance, and scalability of Kokomodo's cell-based cacao in real-world applications including beverages, dairy, and confectionery.

Scale indicators10 records

Recent moves7 records

Expansion highlights7 records

Direct peers

• Lonza Group: Global leader in cell and gene therapy CDMO services with established GMP manufacturing infrastructure. Directly comparable to PluriCDMO as a multi-jurisdictional cell therapy contract manufacturer serving pharma and biotech clients from preclinical through commercial stages.
• Catalent (Novo Holdings): Major CDMO with dedicated cell therapy manufacturing capabilities across multiple geographies. Comparable to PluriCDMO in offering end-to-end cell therapy process development, GMP manufacturing, and fill-finish services for clinical and commercial-stage partners.
• Mesoblast: Allogeneic, off-the-shelf cellular medicine company developing mesenchymal lineage cell therapies (remestemcel-L) for inflammatory and immune-mediated diseases. Most directly comparable to PluriHealth's PLX-PAD and PLX-R18 as a late-stage allogeneic MSC-based therapy developer.
• Athersys: Clinical-stage biotechnology company developing MultiStem, an allogeneic, off-the-shelf stem cell therapy platform. Closely comparable to Pluri's PLX platform in mechanism (multipotent adult progenitor cells), allogeneic/off-the-shelf positioning, and clinical indication overlap in inflammatory and ischemic conditions.
• WuXi Advanced Therapies: Cell and gene therapy CDMO business of WuXi AppTec offering process development, GMP manufacturing, and testing services. Directly comparable to PluriCDMO as a global cell therapy contract manufacturer serving biotech and pharmaceutical clients.
• Nkarta: Clinical-stage biopharmaceutical company engineering allogeneic natural killer (NK) cell therapies for autoimmune and oncology indications. Comparable to Pluri's MAIT cell platform as a peer allogeneic immune cell therapy developer targeting oncology with off-the-shelf cell products.
• Fate Therapeutics: Clinical-stage biopharmaceutical company developing off-the-shelf, iPSC-derived cell therapies for cancer and autoimmune disorders. Comparable to Pluri's MAIT cell immunotherapy platform as a competing allogeneic, ready-to-use cell therapy approach targeting solid tumors.

Broad incumbents

• Ginkgo Bioworks: Cell programming and biosecurity platform serving industries including food/agriculture, industrial biotech, and pharmaceuticals. Comparable to Pluri's broader strategy of leveraging cell biology platforms across pharma, food, and agtech verticals, though at much larger scale and broader scope.

Emerging players

• Upside Foods: Leading cultivated meat company producing cell-based chicken and other meat products. Comparable to Pluri's Ever After Foods JV as a competitor in the cultivated meat category targeting commercial-scale cellular agriculture production.
• Cellares: Emerging cell therapy manufacturing automation company offering the Cell Shuttle integrated manufacturing platform. Comparable to PluriCDMO's automated closed-system bioreactor offering as a next-generation cell therapy manufacturing solution targeting the same CDMO and in-house manufacturer customer base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/pluribiotech
• YouTubeyoutube.com/channel/UC65WAbsbyKFNqvWWkfWZkKQ
• LinkedInlinkedin.com/company/pluri-biotech
• Facebookfacebook.com/profile.php

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries5 records

Funding overview

Funding rounds14 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pluri